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Rationale and Hypothesis: Idiopathic pulmonary fibrosis is a fatal
disease with a variable rate of progression. We hypothesized that
changes in distance walked and quantity of desaturation during a
six-minute-walk test (6MWT) would add prognostic information to
changes in FVC or diffusing capacity for carbon monoxide.
Methods:Onehundredninety-sevenpatientswith idiopathic pulmo-
nary fibrosis were evaluated. Desaturation during the 6MWT was
associated with increased mortality even if a threshold of 88%
was not reached. Baseline walk distance predicted subsequent walk
distance but was not a reliable predictor of subsequent mortality
in multivariate survival models. The predictive ability of serial
changes in physiology varied when patients were stratified by the
presence/absence of desaturation 88% during a baseline 6MWT.
For patients with a baseline saturation  88% during a 6MWT,
the strongest observed predictor of mortality was serial change in
diffusing capacity for carbon monoxide. For patients with satura-
tion  88% during their baseline walk test, serial decreases in FVC
and increases in desaturation area significantly predicted subse-
quentmortality,whereas decreases inwalk distance and in diffusing
capacity for carbon monoxide displayed less consistent statistical
evidence of increasing mortality in our patients.
Conclusion: These data highlight the importance of stratifying pa-
tients by degree of desaturation during a 6MWT before attributing
prognostic value to serial changes in other physiologic variables.
Keywords: idiopathic pulmonary fibrosis; six-minute-walk test;
prognosis; pulmonary function; survival
Idiopathic pulmonary fibrosis (IPF) is a uniformly fatal disease
with a variable rate of progression. Identification of readily avail-
able baseline and short-term serial predictors of survival is criti-
cal for physicians and patients considering options such as lung
transplantation and for the investigation of novel treatments.
Recent studies have suggested several demographic (age, smok-
ing), physiologic (diffusion capacity for carbonmonoxide [DlCO],
FVC, and desaturation), radiologic (high-resolution computed
tomography [HRCT] fibrosis score), and histopathologic (fibro-
blastic foci) features are associated with survival (1–7). Serial
change in FVC adds additional prognostic information to data
obtained at baseline (8–11).
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A central feature in the pathophysiology of IPF is impaired
gas exchange, whichworsenswith exercise (12, 13). This exercise-
induced widening of alveolar arterial O2 gradient and fall in PaO2
is believed to be secondary to multiple abnormalities, including
V˙/Q˙ mismatch, decreased PvO2 and venous admixture (12–16).
The six-min-walk test (6MWT) is a safe procedure for patients
with IPF. Baseline desaturation during a 6MWT is a powerful
predictor of subsequent mortality (4, 6, 7). The relative simplic-
ity, low cost, and reproducibility (7) of the 6MWT makes it an
attractive modality for the longitudinal study of patients with
IPF.
Given these data, we elected to examine the prognostic value
of a baseline and serial changes in 6MWT in relation to changes
in FVC and DlCO in patients with IPF. We hypothesized that
changes in distance walked and quantity of desaturation would
add prognostic value to change in FVC or DlCO.
METHODS
Patient Selection
The study used patients in the database of the University of Michigan
Specialized Center of Research in the Pathobiology of Fibrotic Lung
Disease. Patients in this database were referred for enrollment in study
protocols for suspected IPF based on typical symptoms and on physio-
logic and radiographic findings. Patients with an HRCT scan showing
a definite pattern of usual interstitial pneumonia (11, 17) were not
required to undergo a surgical lung biopsy (n  51). Patients were
treated with varied treatment regimens, including no therapy, predni-
sone alone, prednisone with azathioprine or cyclophosphamide, or zi-
leuton. The lack of a prospectively defined treatment regimen and the
overlap between treatment regimens in some patients precluded our
ability to evaluate the effect of treatment on serial change in pulmonary
function, 6MWT, or survival. We excluded patients with underlying
connective tissue disease, obvious occupational exposure, or a histo-
pathologic pattern other than usual interstitial pneumonia. Approval
for the use of these data was obtained from the Institutional Review
Board of the University of Michigan. A subgroup of these patients has
been previously described (3, 4, 11, 18–21).
Pulmonary Function and 6MWT
Pulmonary function tests including FVC, DlCO, and 6MWT were
performed as previously described (4, 22). Desaturation area (DA;
Figure 1) was defined as the total area above the curve created using
desaturation percentage values observed during each minute of the
6MWT, thereby summing up the differences between a SaO2 of 100%
and the patient’s SaO2 at each minute. For example, a patient with a
SaO2 of 98% at each minute during the 6MWT would have a DA of 12
(100 – 98  2  6 min  12). For safety, we stopped the 6MWT when
patients reached a SaO2 of 86%, and a desaturation score of 14% was
assigned for that minute and all subsequent minutes of the 6MWT. A
higher DA indicates higher overall quantity of desaturation during the
6MWT.
Statistical Analysis
For each patient, 6-mo 6MWT distance walked, DA, FVC, FVC %
predicted, DlCO and DlCO % predicted values were obtained as a result
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Figure 1. Desaturation area (DA) was defined as the total area above
the curve created using desaturation percentage values observed at
baseline and at each subsequentminute of the six-min-walk test (6MWT;
i.e., summing up the differences between an SaO2 of 100% and the
patient’s SaO2 at each minute). For example, a patient with an SaO2 of
98% at each minute during the 6MWT would have a DA of 12. For
safety, we stopped the 6MWT when patients reached an SaO2 of 86%,
and a desaturation score of 14% was assigned for that minute and all
subsequent minutes of the 6MWT. A higher DA indicates higher overall
quantity of desaturation during the 6MWT.
of fitting individual regression lines, provided that each patient was
able to perform at least two 6MWT within the first 12 mo of follow-up
and was alive at the 6-mo time mark. Using the log-rank test, survival
experiences were compared overall and in the two groups with baseline
SaO2  88% or  88%. Univariate and multivariate Cox regression
models adjusting for baseline and serial changes in distance walked,
DA, FVC, FVC% predicted, DlCO, and DlCO % predicted values were




The baseline characteristics for the 197 patients in this study are
outlined in Table 1. A total of 51 patients were diagnosed based
TABLE 1. BASELINE CHARACTERISTICS FOR 197 PATIENTS WITH IDIOPATHIC
PULMONARY FIBROSIS
All Patients SaO2  88% SaO2  88%
(n  197) (n  104) (n  93) p Value
Age, yr 63 (10)* 62 (10) 64 (10) 0.37
Male/female 127/70 65/39 62/31  0.001
Smokers, yes/no/NA 141/53/3 72/29/3 69/24/0 0.23
Pack-years 23 (26) 21 (25) 25 (26) 0.33
FVC, L 2.54 (0.86) 2.74 (0.91) 2.32 (0.76) 0.001
FVC, %predicted 65 (17) 70 (17) 60 (16)  0.001
DLCO, mm/min/mm Hg 11.27 (4.29) 13.68 (4.41) 9.08 (2.88)  0.001
DLCO, %predicted 45 (15) 52 (15) 36 (11)  0.001
Walk distance, ft 928 (534) 1314 (355) 497 (333)  0.001
Walk  600 ft 329 (136) 362 (220) 328 (134) 0.81
n  72 n  3 n  69
Walk between 600 and 1,200 ft 945 (155) 981 (141) 886.98 (162) 0.04
n  50 n  31 n  19
Walk at least 1,200 ft 1,491 (226) 1,502 (230) 1,349 (57)  0.001
n  75 n  70 n  5
Desaturation area (10 U) 5.52 (1.99) 3.98 (1.46) 7.23 (0.68)  0.001
Definition of abbreviations: DLCO  diffusing capacity for carbon monoxide; NA  not available.
* Values are means with SD given in parentheses.
on a typical HRCT and appropriate clinical scenario, whereas
146 were diagnosed with the use of surgical lung biopsy (SLB).
On average, patients with an HRCT diagnosis were older (66 
10 vs. 62  10 yr; p  0.008) and had a greater exposure to
tobacco (38  31 vs. 19  23 pack-years, p  0.001) compared
with patients undergoing surgical lung biopsy. There were no
differences in FVC, FVC % predicted, DlCO, DlCO % predicted,
DA, or proportion of patients with a saturation  88% during
the 6MWT in patients with compared with those without an
SLB (data not shown). When comparing groups with SaO2 below
or above 88% at any time during the 6MWT, no significant
differences were detected in terms of patient age at enrollment,
proportion of smokers, or number of pack-years. Patients with
SaO2  88% throughout the 6MWT were more likely to be
female; had significantly higher FVC, FVC % predicted, DlCO,
and DlCO % predicted values; and walked significantly further,
with a significantly lower DA, compared with patients with a
SaO2  88% at any point during the 6MWT. Most patients with
a SaO2  88% during the 6MWT were stopped before 6 min
because they reached a SaO2 of 86%. Of the 93 patients in the
SaO2 88% group, 84 stopped before completion of the baseline
6MWT. In contrast, 101 of the 104 patients with a baseline
SaO2  88% throughout the entire 6MWT completed 6 min of
ambulation.
Based on the distance walked during the initial 6MWT, the
197 patients were classified into three groups based on thresholds
(600 and 1,200 ft). These thresholds were chosen a priori based
on their approximation to tertiles (actual tertiles between 560
and 580 ft and between 1,246 and 1,260 ft) and for simplicity
because they illustrate 100 ft/min structural increments. BD1
was defined as a walk distance of at most 599 ft, BD2 was defined
as a walk distance between 600 and 1,199 ft, andBD3was defined
as a walk distance of at least 1,200 ft. Categorical baseline walk
distance was a weak predictor of subsequent mortality in the
entire cohort (p 0.038) (Figure 2). Pair-wise comparisons indi-
cate better survival in BD3 patients compared with BD1 patients
(p  0.011). However, the observed difference in survival for
BD2 patients was not significant when compared with BD1 pa-
tients (p 0.223) or BD3 patients (p 0.199). Baseline distance
categories did not maintain statistical significance when patients
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Figure 2. Kaplan-Meier survival
curves for 197 patients with
idiopathic pulmonary fibrosis
stratified by baseline walk dis-
tance (circles  censored, solid
line  walked 1–599 ft, con-
tinuous dashed line  walked
600–1199 ft, broken dashed
line walked at least 1,200 ft).
were stratified by the presence/absence of a SaO2  88% during
the 6MWT (p  0.94 when SaO2  88%; p  0.43 when SaO2 
88%). Similar mortality patterns were seen when baseline dis-
tance walked was evaluated as a continuous variable, with sig-
nificant prediction ofmortality in a univariateCoxmodel (hazard
ratio [HR], 0.94; p  0.005, 100-ft increase) that vanished in
multivariate Cox models. These data suggest that baseline
distance walked has little to no predictive value for predicting
subsequent mortality when accounting for the stronger predictor
of degree of desaturation at baseline.
Unlike distancewalked, evenmild baseline desaturation (SaO2
remained  88% throughout the 6MWT, but DA increased)
was a powerful predictor of subsequent mortality. Patients with
a SaO2  88% during their initial 6MWT had a median survival
time of 3.21 yr, which was lower than the 6.83 yr for those with
baseline SaO2 88% (p 0.006). A 10-point increase in baseline
DA was predictive in the group of patients with initial SaO2 
88% (univariate HR, 1.33; 95% confidence interval [CI], 1.08–
1.63; p  0.007). The magnitude and direction of this DA HR
remained similar in a multivariate model adjusting for distance
walked in feet, DlCO, FVC, age, sex, and smoking years (HR,
1.30; 95% CI, 0.97–1.75; p  0.08], with marginal statistical sig-
nificance; possibly due to the strong negative correlation between
baseline DA and DlCO (  	0.34; p  0.001). These data
confirm the importance of desaturation on subsequent mortality
and highlight that even mild desaturation as measured by DA
is an important predictor of subsequent mortality in patients not
reaching the standard SaO2 88% endpoint during their baseline
walk.
Serial Change Data
We examined if 6-mo changes in DA, FVC, distance walked, and
DlCO were predictive of subsequent mortality. Separate models
adjusting for baseline values and 6-mo change were constructed
for each of these variables.
Analysis of longitudinal walk distance by baseline walk dis-
tance categories revealed stark differences in how these groups
behave over time (as shown in Figures E1a–E2c in the online
supplement). Minimal change over time was observed for BD1
andBD3 patients, with BD1 patients showing little improvement
and themajority of BD3 patients maintaining their baseline walk
distance. However, trajectories for BD2 patients displayed more
fluctuations in serial walk distance over time. Of the 72 patients
in BD1, nearly all (n  69) developed an SaO2  88% at some
point during the 6MWT. In contrast, nearly all patients in BD3
had an SaO2 that remained  88% (n  70 of 75). Patients in
BD2 demonstrated a mix of SaO2 above (n  31) or below 88%
(n  19).
We evaluated the association of changes in distance walked,
DA, FVC, and DlCO with subsequent mortality using univariate
Cox models accounting for the baseline value. These patterns
varied according to SaO2 categorization during their baseline
walk (Table 2). In the subgroup of patients with a SaO2  88%
throughout the 6MWT, adjusting for baseline values, increased
mortality was observed with a decrease of more than 200 ft
in distance walked, worsening of DA treated as a continuous
measurement, a 10% relative decrease in FVC, and a 15% rela-
tive decrease in DlCO. In the group of patients with a SaO2 88%,
during their baseline 6MWT only a decrease in DlCO emerged as
predicting subsequent mortality; changes in FVC, DA, or walk
distance were not predictive in this group. The prognostic value
of DlCO remained statistically significant after making additional
multivariate adjustments for age, sex, and smoking history at
baseline (HR, 2.95; 95% CI, 1.29–6.76; p  0.01). Serial pre-
dictors uniformly outpredicted their baseline counterparts in
terms of statistical and clinical significance.
When each set of serial predictors identified in the subgroup
of patients with an SaO2  88% throughout the 6MWT were
added to a multivariate model together in pairs and adjusted
for age, sex, and smoking history, the magnitude and direction
of most hazards were similar. Exceptions were DlCO, which lost
statistical significance when paired with serial FVC or serial DA,
and WD, which lost statistical significance when paired with DA
(Table 3). Baseline DA increased statistical significance when
interpreted alongside serial DA in multivariate models. Serial
FVC and serial DA measures maintained statistical significance
in all pairwise models.
In patients with an SaO2 88%, during their baseline 6MWT
only a relative decrease in DlCO of at least 15% consistently
predicted subsequent mortality, although a decrease in WD of
at least 200 ft was significant when paired with DA (Table 4).
Limitations in the sample size of our study precluded studying
triplets of serial predictors in a single multivariate model.
DISCUSSION
IPF is a uniformly fatal disease with a variable rate of progres-
sion. In this study, we explored the impact of baseline and serial
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TABLE 2. UNIVARIATE SURVIVAL MODELS EXPLORING SERIAL CHANGES IN WALK DISTANCE,
DESATURATION AREA, FVC, AND DLCO WHEN ADJUSTING FOR BASELINE VALUES
n Hazard Ratio (95% CI) p Value
Patients with baseline SaO2  88%
Baseline walk distance 68 0.89 (0.78–1.02) 0.094
Decrease in WD  200 ft 17 4.81 (1.75–13.19) 0.002
Increase in WD or decrease  200 ft 51 1.00 REF
Baseline DA, 10 U 70 1.73 (1.17–2.54) 0.006
DA relative change 70 3.47 (1.667.25) 0.001
Baseline FVC, % predicted 86 0.41 (0.04–3.83) 0.435
Decrease in FVC (% predicted) relative change  10% 20 3.57 (1.57–8.10) 0.002
Increase in FVC (% predicted) relative change or decrease  10% 66 1.00 REF
Baseline DLCO, % predicted 70 0.19 (0.01–2.90) 0.233
Decrease in DLCO (% predicted) relative change  15% 10 3.73 (1.44–9.65) 0.007
Increase in DLCO (% predicted) relative change or decrease  15% 60 1.00 REF
Patients with baseline SaO2  88%
Baseline walk distance 48 0.95 (0.84–1.08) 0.443
Decrease in WD  200 ft 16 2.25 (0.85–5.95) 0.103
Increase in WD or decrease  200 ft 32 1.00 REF
Baseline DA, 10 U 57 0.83 (0.43–1.60) 0.583
DA relative change 57 0.53 (0.06–4.78) 0.590
Baseline FVC, % predicted 74 0.54 (0.07–4.38) 0.564
Decrease in FVC (% predicted) relative change  10% 18 1.66 (0.76–3.64) 0.208
Increase in FVC (% predicted) relative change or decrease  10% 56 1.00 REF
Baseline DLCO, % predicted 61 0.32 (0.01–10.05) 0.514
Decrease in DLCO (% predicted) relative change  15% 14 3.23 (1.41–7.37) 0.006
Increase in DLCO (% predicted) relative change or decrease  15% 47 1.00 REF
Definition of abbreviations: CI  confidence interval; DA  desaturation area; REF  reference group; WD  walk distance.
changes in FVC, DlCO, DA, and walk distance on subsequent
survival in a large cohort of patients with IPF, including those
diagnosed with typical HRCT and those requiring SLB for diag-
nosis. We demonstrate that (1) subtle desaturation defined by
increased DA during a baseline 6MWT (without reaching a
threshold of  88%) increases the risk of subsequent mortality
even if saturation remains greater than 88%; (2) baseline walk
distance is a reasonable predictor of subsequent walk distance
but does not consistently predict risk of subsequent mortality
in multivariate analyses; and (3) the predictive ability of serial
change in FVC, DlCO, walk distance, and DA varies when pa-
tients are stratified by the presence/absence of desaturation
greater than 88% during a baseline 6MWT. A graphical repre-
sentation of the how serial change in DlCO, FVC, walk distance,
andDAvaries when stratified by the presence/absence of desatu-
ration greater than 88% during a baseline 6MWT is provided
in Figure 3. These data provide clear guidance for the care and
study of patients with IPF.
Our data highlight that even mild desaturation is a risk factor
for subsequent mortality. Previous studies demonstrate that de-
saturation during a 6MWT is associated with increased risk of
subsequent mortality when evaluated as a continuous variable
(6, 23) or using a threshold of  88% (4, 7). Furthermore, the
latter threshold was noted to be a reproducible parameter during
short-term testing (7). In the current study, we extend these
findings by illustrating that even subtle degrees of desaturation,
as assessed by DA, increases a patient’s risk for subsequent
mortality even if a threshold of 88% is not surpassed. A recent
study has used a similar approach as an endpoint of a therapeutic
trial, although mortality was not rigorously assessed during this
short-term study (24).
Baseline distance walked failed to be a strong predictor of
subsequent mortality once information on SaO2 was accounted
for. This finding differs from previous studies (6, 23) and likely
reflects differences in walk protocols. In the current study, pa-
tients were tested without supplemental oxygen, and the walk
was halted if SaO2 decreased to 86%. Previous studies allowed the
use of supplemental oxygen and also tolerated greater degrees of
desaturation (6, 23). In the current study, 87 (44%) of the patients
failed to complete the 6MWT; 84 (97%) of these patients were
stopped due to an SaO2 of less than 86%. The early termination
of the 6MWT due to desaturation may have diluted the possible
effects of walk distance as an outcome measure.
Baseline walk distance tended to predict subsequent walk
distance in that patients with a high level of performance (long
walk distance) tended to preserve their walk distance throughout
the study, whereas patients with poor performance (short walk
distance) rarely improved. The most variation in change in walk
distance was in the group of patients with an intermediate base-
line walk distance. This illustrates the importance of baseline
function when considering walk distance as an outcome measure
in clinical trials for patients with IPF. These data suggest that
“ceiling” (patients too mild to get detectably better with treat-
ment) and “basement” (patients too sick to get detectably better
with currently available treatment) exist when change in 6MWT
distance is used as an outcome variable. This effect has been
reported in studies of patients with primary pulmonary hyperten-
sion where patients with a higher baseline 6MWT distance
showed less improvement in distance walked when treated with
an endothelin receptor antagonist (25). It is possible that pulmo-
nary hypertension was present in some of the more severe pa-
tients in our population. These concepts are important because
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TABLE 3. MULTIVARIATE COX SURVIVAL MODELS EXPLORING THE PAIRWISE PREDICTIVE VALUE
OF SERIAL CHANGES IN WALK DISTANCE, DESATURATION AREA, FVC, AND DLCO IN PATIENTS
WITH IDIOPATHIC PULMONARY FIBROSIS AND AN SaO2  88% THROUGHOUT A BASELINE
6-MIN-WALK TEST
n Hazard Ratio (95% CI) p Value
Baseline FVC, % predicted 68 0.21 (0.01–8.61) 0.408
Baseline WD, 100 feet units 68 0.96 (0.82–1.13) 0.644
Decrease FVC (% predicted) relative change  10% 13 3.01 (1.03–8.79) 0.043
Increase in FVC (% predicted) relative change or decrease  10% 55 1.00 REF
Decrease in WD  200 ft 17 5.12 (1.70–15.36) 0.004
Increase in WD or decrease  200 ft 51 1.00 REF
Baseline FVC, % predicted 69 0.34 (0.02–7.19) 0.490
Baseline DA, 10 U 69 2.03 (1.24–3.31) 0.005
Decrease FVC (% predicted) relative change  10% 14 3.98 (1.27–12.46) 0.018
Increase in FVC (% predicted) relative change or decrease  10% 55 1.00 REF
DA relative change, 10% U 69 1.10 (1.02–1.19) 0.019
Baseline FVC, % predicted 70 0.23 (0.01–9.09) 0.436
Baseline DLCO, % predicted 70 0.04 (0.01–1.24) 0.066
Decrease FVC (% predicted) relative change  10% 15 4.82 (1.30–17.81) 0.018
Increase in FVC (% predicted) relative change or decrease  10% 55 1.00 REF
Decrease in DLCO (% predicted) relative change  15% 10 1.39 (0.46–4.18) 0.559
Increase in DLCO (% predicted) relative change or decrease  15% 60 1.00 REF
Baseline DA, 10 U 62 2.59 (1.35–4.95) 0.004
Baseline DLCO, % predicted 62 2.42 (0.05–117.02) 0.656
DA relative change, 10% U 62 1.17 (1.05–1.30) 0.004
Decrease in DLCO (% predicted) relative change  15% 9 1.06 (1.00–1.12) 0.101
Increase in DLCO (% predicted) relative change or decrease  15% 53 1.00 REF
Baseline DLCO, % predicted 60 0.07 (0.01–3.41) 0.177
Baseline WD, 100 feet units 60 0.87 (0.75–0.99) 0.044
Decrease in DLCO (% predicted) relative change  15% 8 6.47 (1.68–24.87) 0.007
Increase in DLCO (% predicted) relative change or decrease  15% 52 1.00 REF
Decrease in WD  200 ft 15 7.94 (2.28–27.65) 0.001
Increase in WD or decrease  200 ft 45 1.00 REF
Baseline DA, 10 U 68 1.40 (0.79–2.48) 0.253
Baseline WD, 100 feet units 68 0.90 (0.77–1.06) 0.199
DA relative change, 10% U 68 1.13 (0.99–1.28) 0.067
Decrease in WD  200 ft 17 2.38 (0.63–8.96) 0.201
Increase in WD or decrease  200 ft 51 1.00 REF
For definition of abbreviations, see Table 2.
Values are adjusted for age, sex, and smoking history at baseline.
6-min walk testing has become increasingly used as an outcome
measure in IPF therapeutic trials (24, 26).
Our data illustrate that the predictive ability of serial change
inFVCorDlCO varieswith baseline desaturation during exercise.
In univariate Cox models among patients with a baseline SaO2
greater than 88% during the 6MWT, we observed an increased
risk of subsequent mortality associated with a relative decrease
in FVC of 10%, a relative decrease in DlCO of 15%, a decrease
in walk distance of at least 200 ft, or an increase in DA. In the
group of patients with a baseline SaO2 88%, during the 6MWT
only a serial decline in DlCO predicted subsequent mortality.
This variability was also reflected in multivariable models where
the predictive ability of these variables changed depending on
patient stratification by the level of baseline desaturation. This
suggests that in a group of patients already at risk for subsequent
mortality (i.e., SaO2 88%) (4), serial change in DlCO can further
refine the prognosis, whereas change in DA, walk distance, and
FVC do not. In contrast, in patients with a baseline SaO2 during
a 6MWT greater than 88%, a decrease in walk distance of at
least 200 ft, a relative decrease in FVC of at least 10%, and
relative decrease in DA predicted subsequent mortality to vary-
ing degrees, whereas change in DlCO was less useful. These data
extend the concept that serial change in FVC is most predictive
of subsequent mortality in IPF longitudinal studies (8–11, 27)
and provide a rationale for previously discordant observations
regarding the predictive ability of DlCO (8, 9, 11). These data
highlight the importance of stratification by baseline level of
desaturation when selecting dynamic outcomemeasures for clin-
ical trials and/or patient treatment decisions. These concepts
should prove valuable in decision making during clinical care,
in optimizing timing of lung transplantation, and in the design
and conduct of therapeutic trials in patients with IPF.
The explanation for the variable predictive ability of FVC
orDlCO based on stratification by degree of desaturation remains
conjectural. Although FVC and DlCO are related, they reflect
different aspects of pulmonary physiology. The degree of restric-
tion is reflected by FVC, whereas abnormal gas exchange, which
can involve pulmonary vasculopathy or mismatches in ventila-
tion and perfusion, is reflected by DlCO. Patients with a baseline
SaO2  88% during a 6MWT had a lower FVC compared with
patients with saturation above 88%. Therefore, we initially con-
sidered that their FVC was already decreased to a level where
further change was unlikely. This is not a likely explanation
because a similar number of patients experienced a decline in
FVC of at least 10% even when patients were stratified by
baseline desaturation. Previous studies have also illustrated that
patients may remain stable for prolonged periods of time and
then present with an acute exacerbation and death (27–29).
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TABLE 4. MULTIVARIATE COX SURVIVAL MODELS EXPLORING THE PAIRWISE PREDICTIVE VALUE
OF SERIAL CHANGES IN WALK DISTANCE, DESATURATION AREA, FVC, AND DLCO IN PATIENTS
WITH IDIOPATHIC PULMONARY FIBROSIS WHO EXPERIENCED A SATURATION  88% DURING A
BASELINE 6-MIN-WALK TEST
n Hazard Ratio (95% CI) p Value
Baseline FVC, % predicted 49 0.13 (0.01–4.41) 0.259
Baseline WD, 100 feet units 49 1.00 (0.87–1.15) 0.996
Decrease FVC (% predicted) relative change  10% 10 1.34 (0.41–4.39) 0.633
Increase in FVC (% predicted) relative change or decrease  10% 39 1.00 REF
Decrease in WD  200 ft 15 1.72 (0.59–4.98) 0.320
Increase in WD or decrease  200 ft 34 1.00 REF
Baseline FVC, % predicted 54 0.06 (0.01–2.14) 0.124
Baseline DA, 10 U 54 0.64 (0.28–1.49) 0.304
Decrease FVC (% predicted) relative change  10% 13 1.95 (0.62–6.13) 0.255
Increase in FVC (% predicted) relative change or decrease  10% 41 1.00 REF
DA relative change, 10% U 54 0.87 (0.66–1.15) 0.322
Baseline FVC, % predicted 61 0.60 (0.02–14.73) 0.752
Baseline DLCO, % predicted 61 0.40 (0.01–27.36) 0.669
Decrease FVC (% predicted) relative change  10% 13 0.87 (0.29–2.61) 0.803
Increase in FVC (% predicted) relative change or decrease  10% 48 1.00 REF
Decrease in DLCO (%f predicted) relative change  15% 14 3.08 (1.25–7.55) 0.014
Increase in DLCO (% predicted) relative change or decrease  15% 47 1.00 REF
Baseline DA, 10 U 47 0.67 (0.25–1.77) 0.414
Baseline DLCO, (% predicted) 47 0.25 (0.01–54.06) 0.609
DA relative change (10% units) 47 0.80 (0.59–1.15) 0.165
Decrease in DLCO (% predicted) relative change  15% 9 5.77 (1.66–20.05) 0.006
Increase in DLCO (% predicted) relative change or decrease  15% 38 1.00 REF
Baseline DLCO, % predicted 44 0.20 (0.01–85.07) 0.602
Baseline WD, 100 feet units 44 1.12 (0.94–1.34) 0.197
Decrease in DLCO (% predicted) relative change  15% 9 7.72 (1.42–41.95) 0.018
Increase in DLCO (% predicted) relative change or decrease  15% 35 1.00 REF
Decrease in WD  200 ft 14 0.41 (0.07–2.31) 0.313
Increase in WD or decrease  200 ft 30 1.00 REF
Baseline DA, 10 U 51 0.41 (0.12–1.43) 0.162
Baseline WD, 100 feet units 51 0.83 (0.66–1.05) 0.119
DA relative change, 10% U 51 0.87 (0.66–1.15) 0.339
Decrease in WD  200 ft 16 3.67 (1.12–12.07) 0.032
Increase in WD or decrease  200 ft 35 1.00 REF
For definition of abbreviations, see Table 2.
Values are adjusted for age, sex, and smoking history at baseline.
Figure 3. Graphic representation of how the predictive ability of serial
changes in FVC, diffusion capacity of carbon monoxide (DLCO), change
in walk distance, and change in desaturation varies by the presence/
absence of desaturation to 88% during a baseline 6MWT. These data
suggest that decline in DLCO over 6 mo is the sole predictor of increased
risk of subsequent mortality and that declines in DLCO, FVC, walk dis-
tance, and worsening desaturation can be used to follow patients who
do not desaturate  88% during a baseline 6MWT.
Further research is required to understand themechanisms asso-
ciated with decline in pulmonary physiology and subsequent
mortality.
Strengths of this study include a large sample size and the
inclusion of patients with an SLB and also patients with a typical
HRCT not requiring a SLB for diagnosis. This latter point re-
flects the usual care of patients with IPF and helps generalize
the results of this study. Weaknesses of this study include its
retrospective study design, the lack of predefined data collection
points, the format for terminating 6-min walk testing based on
saturation, and the lack of prospectively defined treatment regi-
mens. The effect of varied treatments on study outcome is likely
minimal given the lack of rigorous, positive efficacy data for
the treatments used during the course of this study. Additional
prospective data collection is required to confirm our findings.
In conclusion, this study highlights that desaturation at base-
line increases the risk of subsequent mortality; baseline walk
distance is a good predictor of subsequent walk distance but
does not reliably predict risk of subsequent mortality; and the
predictive ability of serial change in FVC, DlCO, walk distance,
and DA varies when patients are stratified by the presence/
absenceof a saturation greater than 88%during a baseline 6MWT.
This study highlights the importance of stratifying patients by
degree of desaturation at baseline before examining changes in
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physiology as outcomes in clinical trials or when making treat-
ment decisions for individual patients (e.g., when the risk of
subsequent mortality justifies the risk of interventions such as
lung transplantation).
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